RKDA vs XBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

RKDA

39.5
AI Score
VS
XBIO Wins

XBIO

62.5
AI Score

Investment Advisor Scores

RKDA

40score
Recommendation
SELL

XBIO

63score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric RKDA XBIO Winner
Revenue 2.54M 1.47M RKDA
Net Income -10.65M -1.39M XBIO
Net Margin -418.8% -94.5% XBIO
Operating Income -1.27M -1.47M RKDA
ROE -1682.6% -22.8% XBIO
ROA -180.7% -19.9% XBIO
Total Assets 5.89M 6.97M XBIO
Current Ratio 3.49 7.43 XBIO

Relative Price Performance (Last 90 Days)

RKDA 1M: -45.5% · 3M: -61.4% XBIO 1M: -47.4% · 3M: -21.6%

Current Technical Phase

RKDA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -18.3%), weak momentum, RSI 25

RSI (14): 25.0 · Price: $0.28

XBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 35

RSI (14): 34.8 · Price: $2.24

Fundamentals Snapshot

Metric RKDA XBIO
Market Cap — —
Forward P/E -0.1 -6.6
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.1%
Gross Margin 0.3% 1.0%
Operating Margin -0.3% -1.5%
EPS -4.54 -1.12
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XBIO is currently the stronger investment candidate, winning 6 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.